(BW) (IBC) Potential HIV Infection: HIV Turned Against Itself

(BW) (IBC) Potential HIV Infection: HIV Turned Against Itself

BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 8 October 1997.

SOUTHBORO, Mass.--(BW HealthWire)--Oct. 8, 1997--A recent September issue of Cell reports exciting news of a novel anti-HIV-1 strategy involving sophisticatedly engineered viruses that seek and destroy human HIV-1 infected cells only, then move on to seek out and destroy other HIV-1 infected cells. (Mebatsion et al., 1997; Schnell et al., 1997). This and other recent breakthroughs in potential HIV treatments and new HIV co-receptors discoveries is proof that the scientific community is making significant progress towards creating HIV treatments that stop the disease in its tracks.

In the coming months, there will be reports of several new findings in HIV co-receptor understanding and potential HIV treatments. Many of these new research developments will be reported on at IBC's upcoming International Conference on HIV Co-Receptors: Latest Progress in Understanding and HIV Inhibition, November 20 & 21, 1997 at the Westin Washington DC City Center, Washington, DC.

Among the leading academic Researchers that will be presenting are Robert Doms, Ph.D., James Hoxie, Ph.D., John Moore, Ph.D., as well as leading companies such as Glaxo Wellcome, LeukoSite, British Biotech Pharmaceuticals, Berlex Biosciences, Chiron Corp., Cell Genesys, Enzo Biochem, SyStemix and Ribozyme Pharmaceuticals.

For more detailed information on this important industry conference, please contact, Jeffrey Levinson, IBC USA Conferences, 225 Turnpike Road, Southboro, MA 01772. Telephone: 508-481-6400; Fax: 508-481-4473.

Or for more information, on-line, visit our website at www.ibcusa.com/conf/coreceptor

--30--mb/bos

CONTACT: IBC USA Conferences Jeffrey Levinson, 508/481-6400

Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com

Keywords: MASSACHUSETTS MEDICINE PHARMACEUTICAL BIOTECHNOLOGY

Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
971008
BW971005

Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .